Nkarta to webcast initial NKX019 data in autoimmune disease at ACR 2026

Nkarta, Inc. announced on November 6, 2026 that it will hold a webcast on Monday, November 9, 2026 at 8:00 a.m. Eastern Time to discuss initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis being presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.¹

The data come from two registered studies. Ntrust-1 (NCT06557265) and Ntrust-2 (NCT06733935) are multi-center, open-label, dose-escalation trials in patients with autoimmune disease who receive lymphodepletion followed by CD19-targeted CAR-NK cell therapy.¹ The trials are designed to test the safety of NKX019 and to see whether it can produce durable remission by resetting the immune system through elimination of pathogenic B cells.¹

Enrollment spans several conditions. The Ntrust trials plan to enroll up to 12 patients per dose level per disease, with myositis and systemic sclerosis as the lead indications, alongside ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, and primary membranous nephropathy.¹ The company may enroll additional patients if needed to refine the populations studied further.¹

Dosing in both studies follows a set pattern. Patients receive a three-dose cycle of NKX019 after lymphodepletion with fludarabine and cyclophosphamide, or cyclophosphamide alone for those with significant baseline cytopenia, an approach meant to test single-agent activity and support a faster route to regulatory approval.¹ Patients in both trials may receive extra cycles if needed to restore or deepen their response.¹

NKX019 itself is described as an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate made from natural killer cells taken from the peripheral blood of healthy adult donors.¹ It carries a humanized CD19-directed CAR to improve targeting along with a built-in, membrane-bound IL-15 component meant to extend its persistence and activity without needing outside cytokine support.¹ The webcast replay will later be posted on Nkarta's investor website.